Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Nat Immunol. 2011 Oct 9;12(11):1063-70. doi: 10.1038/ni.2113.
Leucine-rich repeat kinase 2 (LRRK2) has been identified by genome-wide association studies as being encoded by a major susceptibility gene for Crohn's disease. Here we found that LRRK2 deficiency conferred enhanced susceptibility to experimental colitis in mice. Mechanistic studies showed that LRRK2 was a potent negative regulator of the transcription factor NFAT and was a component of a complex that included the large noncoding RNA NRON (an NFAT repressor). Furthermore, the risk-associated allele encoding LRRK2 Met2397 identified by a genome-wide association study for Crohn's disease resulted in less LRRK2 protein post-translationally. Severe colitis in LRRK2-deficient mice was associated with enhanced nuclear localization of NFAT1. Thus, our study defines a new step in the control of NFAT activation that involves an immunoregulatory function of LRRK2 and has important implications for inflammatory bowel disease.
富含亮氨酸重复激酶 2(LRRK2)已通过全基因组关联研究确定为克罗恩病的主要易感基因所编码。在这里,我们发现 LRRK2 缺乏使小鼠对实验性结肠炎的易感性增强。机制研究表明,LRRK2 是转录因子 NFAT 的有效负调节剂,是包括大非编码 RNA NRON(NFAT 抑制剂)在内的复合物的组成部分。此外,通过针对克罗恩病的全基因组关联研究鉴定的编码 LRRK2 Met2397 的风险相关等位基因导致 LRRK2 蛋白的翻译后减少。LRRK2 缺陷型小鼠的严重结肠炎与 NFAT1 的核定位增强有关。因此,我们的研究定义了 NFAT 激活控制的新步骤,该步骤涉及 LRRK2 的免疫调节功能,对炎症性肠病具有重要意义。